2
|
Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 2014; 29:249-52. [DOI: 10.1038/leu.2014.270] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
3
|
Saliba J, Hamidi S, Lenglet G, Langlois T, Yin J, Cabagnols X, Secardin L, Legrand C, Galy A, Opolon P, Benyahia B, Solary E, Bernard OA, Chen L, Debili N, Raslova H, Norol F, Vainchenker W, Plo I, Di Stefano A. Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. PLoS One 2013; 8:e74257. [PMID: 24066127 PMCID: PMC3774801 DOI: 10.1371/journal.pone.0074257] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 07/29/2013] [Indexed: 12/30/2022] Open
Abstract
JAK2V617F is the predominant mutation in myeloproliferative neoplasms (MPN). Modeling MPN in a human context might be helpful for the screening of molecules targeting JAK2 and its intracellular signaling. We describe here the derivation of induced pluripotent stem (iPS) cell lines from 2 polycythemia vera patients carrying a heterozygous and a homozygous mutated JAK2V617F, respectively. In the patient with homozygous JAK2V617F, additional ASXL1 mutation and chromosome 20 allowed partial delineation of the clonal architecture and assignation of the cellular origin of the derived iPS cell lines. The marked difference in the response to erythropoietin (EPO) between homozygous and heterozygous cell lines correlated with the constitutive activation level of signaling pathways. Strikingly, heterozygous iPS cells showed thrombopoietin (TPO)-independent formation of megakaryocytic colonies, but not EPO-independent erythroid colony formation. JAK2, PI3K and HSP90 inhibitors were able to block spontaneous and EPO-induced growth of erythroid colonies from GPA+CD41+ cells derived from iPS cells. Altogether, this study brings the proof of concept that iPS can be used for studying MPN pathogenesis, clonal architecture, and drug efficacy.
Collapse
Affiliation(s)
- Joseph Saliba
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Sofiane Hamidi
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Gaëlle Lenglet
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Thierry Langlois
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Jingkui Yin
- Beijing Genomic Institute (BGI), Shenzhen, Shenzhen, China
| | - Xénia Cabagnols
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Lise Secardin
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Céline Legrand
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Anne Galy
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 951, University of Évry Val d’Essonne, Genethon, Évry, France
| | - Paule Opolon
- Institut Gustave Roussy, Pathology platform, Villejuif, France
| | - Baya Benyahia
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Unité Fonctionnelle de Génétique Chromosomique, Département de Génétique, Paris, France
| | - Eric Solary
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Olivier A. Bernard
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 985, Villejuif, France
| | - Longyun Chen
- Beijing Genomic Institute (BGI), Shenzhen, Shenzhen, China
| | - Najet Debili
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Hana Raslova
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Françoise Norol
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - William Vainchenker
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
- * E-mail:
| | - Isabelle Plo
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| | - Antonio Di Stefano
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence, Globule rouge-Excellence (GR-Ex), Villejuif, France
- University Paris-Sud 11, Le Kremlin-Bicêtre, France
- Institut Gustave Roussy, Villejuif, France
| |
Collapse
|